Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The CYP2D6 gene determines oxycodone's phenotype-specific addictive potential: implications for addiction prevention and treatment.

Medical hypotheses - 1 Mar 2014

Linares Oscar A, Daly David, Stefanovski Darko, Boston Raymond C

Abstract excerpt

We propose a hypothesis for predicting addictive potential of oral drugs, in general, and oxycodone's addictive potential, in particular. We hypothesize that a patient's CYP2D6 phenotype determines oxycodone's addictive potential, in part, via genotype-specific regulation of its clearance; although, other possible modulators of oxycodone's addiction potential exist. For example, brain CYPs related to phenotype...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Opioid-Related Disorders

Share to Phenotype

Source

Identifiers

PMID: 24495562
DOI: 10.1016/j.mehy.2014.01.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The CYP2D6 gene determines oxycodone's phenotype-specific addictive potential: implications for addiction prevention and treatment.PMID 24495562Read ↗

Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.Semantic proximity Read ↗

Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective MetabolismSemantic proximity Read ↗

Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics, and Pharmacokinetic Dosing.Semantic proximity Read ↗

CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia.Semantic proximity Read ↗

The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.Semantic proximity Read ↗

Fundamental Considerations for GeneticallyGuided Pain Management with Opioids Based on CYP2D6 and OPRM1 PolymorphismsSemantic proximity Read ↗

CYP2D6 phenotype-specific codeine population pharmacokinetics.Semantic proximity Read ↗

CYP2D6 Pharmacogenetic and Oxycodone Pharmacokinetic Association Study in Pediatric Surgical PatientsSemantic proximity Read ↗

The Hypoalgesic Effect of Oxycodone in Human Experimental Pain Models in Relation to the CYP2D6 Oxidation PolymorphismSemantic proximity Read ↗

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)Semantic proximity Read ↗

Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration.Semantic proximity Read ↗

The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.